Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Journal of Neuro-Oncology, 07/02/09
Wen PY et al. - Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma. The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09
Approach to Thrombocytopenia in Older Adults
Geriatrics & Aging, 11/10/09
Update on oral lichen planus
Expert Review of Dermatology, 10/14/09
Sponsor
Article Search
Sponsor


See Latest Articles


